Sonnet BioTherapeutics
4 clinical trials · Sponsor
◉ Watch Sonnet BioTherapeutics
| Record | Firm | Date |
|---|---|---|
| Combination of SON-1010 (IL12-FHAB) and Atezolizumab in Patients With Platinum-resistant Ovarian Cancer (NCT05756907) | Sonnet BioTherapeutics | 2023-09-15 |
| SON-080 in Patients With Persistent Chemotherapy-induced Peripheral Neuropathy (CIPN) (NCT05435742) | Sonnet BioTherapeutics | 2022-10-27 |
| Study of SON-1010 (IL12-FHAB) in Healthy Adults (NCT05408572) | Sonnet BioTherapeutics | 2022-07-27 |
| Phase 1 Study of SON-1010 in Adult Patients With Advanced Solid Tumors (NCT05352750) | Sonnet BioTherapeutics | 2022-04-20 |
Track Sonnet BioTherapeutics automatically
Every clearance here is in the API, with alerts when new ones post.